Clonal Hematopoiesis is a syndrome in which cancer related mutation occur and blood cells containing the
mutation spreads so that more than 2% of the blood cells have the mutation.
As people age, the cells in peoples’ bodies accumulate random mutations, drastically improving clonal
If clonal hematopoiesis occurs, the chance of blood cancer and diseases related to cardiovascular system
drastically increases over that of a healthy individual.
is SD Genomics’ clinical diagnostics test based on NGS(next-generation-sequencing),
using the DNA extracted from blood cells to find clonal hematopoiesis and high-risk group.
tests for the frequently found variants in genes from the results of a large-scale clonal
hematopoiesis study done with a 31-gene panel. After analyzing the DNA extracted from blood cells, if
mutations of 2% or higher have been found in any of the 31 genes, such results are reported as clonal
When clonal hematopoiesis occurs, the chance of blood cancer incidence increases 11 to 13 times
higher than those without, and risk for coronary artery diseases, ischemic stroke, and early myocardial
infarction occurring before age 50, increases by 2~4 times.
Also, the risk for secondary myeloid leukemia increases by 13 ~ 14 times.
SD Genomics performs genetic tests to the requests of medical institutes following the Bioethics and Safety Act. Prior to service request,
understanding the objective of the test, reporting method of the test, and limitations of the test is necessary.
|Required Documents||Test Requirement and Consent form (provided below)|
|TAT||Within 4-6 weeks|
We test the coding exon region of 31 genes reported to be associated with clonal hematopoiesis. All genes and genetic
variations in the test is selected on large-scale studies or on public databases and reported if ratio in which the variant
is found is more than 2%.